Jennison Associates’s SpringWorks Therapeutics SWTX Stock Holding History

Jennison Associates’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,782	Closed	-$652K	–	631
2025 Q1	$652K	Buy	+14,782	New	+$680K	﹤0.01%	524
2021 Q4	–	Sell	-645,521	Closed	-$41M	–	722
2021 Q3	$41M	Buy	645,521 +331,862	+106%	+$25.6M	0.03%	246
2021 Q2	$25.8M	Buy	313,659 +128,574	+69%	+$9.76M	0.02%	336
2021 Q1	$13.6M	Buy	+185,085	New	+$14.5M	0.01%	396
2020 Q2	–	Sell	-253,654	Closed	-$6.85M	–	699
2020 Q1	$6.85M	Buy	253,654 +2,207	+0.9%	+$72K	0.01%	372
2019 Q4	$9.68M	Buy	251,447 +1,246	+0.5%	+$29.2K	0.01%	383
2019 Q3	$5.42M	Buy	+250,201	New	+$5.91M	0.01%	451

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Jennison Associates's SWTX Position: Q2 2025 in Review

Jennison Associates sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 14,782 shares — an estimated $652K sold.

Jennison Associates first reported a position in SWTX in Q3 2019 and held it in 7 quarters. The position peaked at $41M in Q3 2021. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Jennison Associates reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Jennison Associates sold 14,782 SpringWorks Therapeutics shares in Q2 2025, an estimated $652K.
Jennison Associates first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 7 quarters.
Jennison Associates's SpringWorks Therapeutics position peaked at $41M in Q3 2021.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.